Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported an open-market sale of 39,541 shares of Common Stock at a price of $43.15 per share on June 16, 2026. This represents a partial reduction of his direct holdings rather than a full exit.
After the transaction, Moll directly holds 227,296 shares of Arteris common stock. A footnote explains that this total includes 1,307 shares acquired on May 21, 2026 through the company’s Employee Stock Purchase Plan, reflecting ongoing participation in an employee equity program even alongside the reported sale.
AIP filed a Form 144 notice reporting proposed dispositions of Common Stock by an identified selling person.
The filing lists restricted stock vesting entries under a registered plan dated 09/09/2024 (25,850 shares) and 09/03/2024 (13,691 shares), and shows multiple actual sales by Laurent Moll in April 2026, including 13,448, 1,003, 990, 1,552, and 5,602 shares on specific dates with corresponding proceeds.
Arteris, Inc. President and CEO K. Charles Janac reported indirect open-market sales of a total of 70,000 shares of common stock on June 8, 2026. The shares were sold by Bayview Legacy, LLC in two transactions at weighted average prices of $35.1596 and $34.7417, in multiple trades within disclosed price ranges. A footnote states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC held 8,956,622 shares indirectly, while Janac also held 196,729 shares directly and 56,252 shares through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 70,000 shares of AIP common stock. The sales occurred on June 8, 2026 in two tranches at weighted average prices of $34.7417 and $35.1596 per share.
The filing states that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. All holdings are reported as indirect, through Bayview Legacy, LLC, which is controlled by K. Charles Janac as manager.
The filing reports proposed and completed dispositions of Common stock by affiliated holders using 10b5-1 plans and private acquisitions. The excerpt lists multiple 10b5-1 sales by BAYVIEW LEGACY, LLC and one by K. CHARLES JANAC between 03/09/2026 and 05/08/2026, with individual sale quantities and dollar amounts recorded.
The filing also lists earlier private acquisitions from the issuer on 11/05/2013 (50,000 shares) and 02/05/2016 (20,000 shares). Transaction timing and per-sale proceeds are shown next to each sale date.
Arteris, Inc. director Antonio J. Viana reported indirect sales and gifts of Common Stock. On June 4, 2026, the Viana Family Trust, for which he is trustee, executed open-market sales totaling 20,839 shares of Arteris Common Stock in three blocks: 8,939 shares at a weighted average price of $37.089, 7,000 shares at $36.5082, and 4,900 shares at $35.4661, under a Rule 10b5-1 trading plan adopted on June 10, 2025. The filing also reports bona fide gifts totaling 41,678 shares, split between indirect trust holdings and his direct holdings, at a reported price of $0. Following these transactions, Viana reports 85,459 shares held indirectly through the Viana Family Trust and 4,704 shares held directly.
Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation. The award carried no cash exercise price and increased his directly held position to 74,330 shares.
The 4,703 RSUs each represent a contingent right to one share of common stock and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, as long as he continues serving on the board. The grant was based on the average trading price of Arteris stock of $31.89 over the April 21, 2026 to June 2, 2026 period, and Kunkel elected to defer receipt of the shares.
Viana Antonio J reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Antonio J. Viana reported an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholder meeting, conditioned on his continued board service.
The grant was made on June 2, 2026, based on an average trading price of $31.89 for Arteris stock from April 21, 2026 through June 2, 2026. Following the grant, Viana holds 25,543 shares directly, including these RSUs, and 64,620 shares indirectly through the Viana Family Trust.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, if she continues serving on the board. The grant value was based on the average trading price of $31.89 over the period from April 21, 2026 through June 2, 2026. Following this award, she holds a total of 106,414 common shares directly, and has elected to defer receipt of the shares underlying this RSU grant.
Chitkara Raman reported acquisition or exercise transactions in this Form 4 filing.
Arteris director Raman Chitkara reported an equity award of 4,703 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, contingent on continued Board service. Following this award, Chitkara directly holds 147,570 shares, and has elected to defer receipt of the underlying shares once the RSUs vest.